ReviewChildhood kidney diseases2026
The utility and advantages of exome and genome sequencing in pediatric kidney disease diagnosis.
Review in Childhood kidney diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric kidney diseases encompass a diverse group of disorders, ranging from congenital anomalies to glomerulopathies. Unlike adults, where lifestyle factors predominate, approximately 30% of pediatric cases constitute inherited kidney diseases. This high heritability underscores the critical importance of early and accurate genetic testing. While targeted gene panels have historically been the first-line diagnostic tool, they are limited by fixed gene content and an inability to detect complex structural variants. Next-generation sequencing, specifically exome sequencing and genome sequencing, has transformed the diagnostic landscape by enabling an unbiased, simultaneous analysis of all disease-associated genes. These modalities enhance diagnostic yields by identifying structural variants including copy number variants and non-coding variants often missed by conventional panels. Furthermore, they allow for the discovery of novel disease genes through periodic reanalysis. Despite these advancements, a significant diagnostic gap persists due to the limitations of short-read sequencing in complex genomic regions and the difficulty of interpreting variants of uncertain significance. To address these challenges, integrating long-read sequencing to resolve complex genomic regions and implementing systematic reanalysis protocols are recommended. This review provides a comprehensive comparison of diagnostic yields across testing modalities and discusses the future of genomic profiling in pediatric kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.